Presentation:  4:00-5:00PM
Discussion & Reception: 5:00-6:00PM

Speakers from Roche Pharmaceuticals:
Kapil Dhingra, MD, Vice President, Group Leader Oncology
David Heimbrook,  PhD, Vice President, Nutley Oncology Research, Global Therapy Area Head, Oncology
Catherine Wheeler, PhD, Therapeutic Expert for Medical Science - Oncology 

Topics/Compounds:

• Brief Overview Genentech-Roche Relationship
• Late Stage Compounds (Avastin, Herceptin, Rituxan, Xeloda, Tarceva)
• Early Stage Compounds: Omnitarg, Epothilones, CDK Inhibitor, MAI (Mitosis-Angiogenesis Inhibitor)
• Anti IGFR1 Antibody, Selective mutant b-raf Inhibitor
• Glyco-engineered anti CD20 Antibody
• MDM2-p53 interaction inhibitor

Note: Presentations are designated for DF/HCC members only and are not open to the public.

For more information, please contact Petra Loesch at 617-724-3867 or ploesch@partners.org .